EUDRACAP® functional, ready-to-fill HPMC capsules

Functional capsules targeting the ileo-colonic region

EUDRACAP® colon is designed for drug products targeted for release in the ileo-colonic region. Like EUDRACAP® enteric, it provides reliable gastric resistance to protect sensitive ingredients. However, in contrast to EUDRACAP® enteric, which shows fast release at pH 6.8, EUDRACAP® colon provides significantly more delayed release at a higher pH EUDRACAP® colon also provides reliable protection and targeted delivery of sensitive actives like live biotherapeutics, polypeptides and proteins (biologics), and nucleotides.

Functional capsules to reduce risks and variables in preclinical trials

Evonik also offers EUDRACAP® as a tiny capsule suitable for preclinical trials. This capsule is available for enteric protection as EUDRACAP® preclinic enteric. Whenever you need to test an enteric formulation in animal trials, our empty, ready-to-fill, size 9h (5.1 mm) gelatin-based hard capsule is designed to provide robust low gastrointestinal (GI) delivery in preclinical animal models. EUDRACAP® preclinic enteric does not require additional coating steps to achieve enteric functionality, it simplifies the formulation, eliminates the need of additional excipients and banding and, therefore, reduces the variables and risks in preclinical studies. 

EUDRACAP® preclinic enteric uses the same coating technology and has a similar dissolution profile to EUDRACAP® enteric. This means you can move seamlessly from preclinical to clinical and commercial stages, reducing complexity and streamlining the whole drug development process.

Custom capsules for tailored coatings, formulation development and cGMP scale-up

Alongside our standard EUDRACAP® functional coated capsules, we also offer EUDRACAP® Select. This customizable capsule delivers a range of options to match your specific active pharmaceutical ingredient (API), formulation and brand requirements. Different capsule sizes, colors and other tailored options are possible. A range of different EUDRAGIT® polymers, drug delivery technologies and process technologies, as well as other solubility and bioavailability options, are also available to help optimize your release profile.